Ageing, Longevity Capital, and the New Frontier of Power
Biotechnology research focused on extending human healthspan has moved to the forefront of global strategic agendas following a September 2025 conversation between Russian President Vladimir Putin and Chinese leader Xi Jinping. While critics often dismiss such discussions as unrealistic, both nations have spent decades formalizing policies on healthy ageing, investing heavily in gene-editing and 3D bioprinting to address the cellular mechanisms of the ageing process.
The World Health Organization (WHO) estimates that by 2030, the global population of individuals over the age of sixty will reach 1.4 billion, a demographic shift driven by rising life expectancy and declining fertility rates.
The Strategic Shift Toward Longevity Capital
Nations are increasingly viewing demographic decline through a scientific lens, shifting resources toward technologies that mitigate the economic impacts of an ageing workforce. This trend has birthed “longevity capital,” a sector comprising institutional, technological, and financial investments aimed at delaying age-related decline. According to research, this shift is not limited to Russia and China; the United States and India have also established research ecosystems to address the onset of chronic diseases by targeting ageing at the molecular level.
Samantha Carter notes that while the “geriatric peace” theory—proposed by political scientist Mark L. Haas—suggests that ageing populations might reduce the likelihood of international conflict due to diminished military-age cohorts, history offers a more complex view. As seen in Russia’s actions in Georgia and Ukraine, demographic anxiety may actually drive states to act more assertively to protect their interests rather than retreating into a more peaceful foreign policy.
Advancements in Geroscience and AI
Modern geroscience treats ageing as a biological process that can be modified through preventative interventions rather than an inevitable state of decline. A significant milestone occurred in 2013 and 2023, when scientists categorized the “hallmarks of ageing”—the interdependent cellular and molecular mechanisms that drive age-related disorders. This categorization allows for more systematic research into tracking and potentially reversing cellular senescence.
Drug discovery is currently accelerating through the convergence of artificial intelligence and biotechnology. Companies such as NewLimit are exploring epigenetic reprogramming to reverse cellular ageing, while Altos Labs is investigating the use of rapamycin in animal models to slow senescence. In the public sector, the U.S. Advanced Research Projects Agency for Health (ARPA-H) has committed USD 144 million to its PROSPR program to fund studies on ageing interventions.
What Happens Next
As longevity research becomes more deeply embedded in biotech innovation ecosystems, societies may face a fundamental adaptation to longer healthspans. Analysts expect that as biomarkers for age-related diseases become more refined, clinical trials will increasingly focus on early intervention. However, because the WHO does not currently recognize ageing as a disease, the development of therapeutic agents will likely remain tied to the treatment of specific age-related conditions rather than the pursuit of immortality.
Frequently Asked Questions
Is ageing officially considered a disease by health authorities?
No, the World Health Organization does not recognize ageing as a disease. Consequently, current clinical trials focus on factors that contribute to specific age-related diseases rather than treating ageing as a direct therapeutic indication.
What is the “geriatric peace” theory?
Proposed by political scientist Mark L. Haas, the theory suggests that as major economies experience demographic aging, they will be less likely to engage in conflict due to constrained economic growth and a shrinking military-age cohort. However, recent geopolitical events, such as Russia’s conflicts in Georgia and Ukraine, suggest this theory does not always hold true in practice.
How are governments participating in longevity research?
Governments are funding longevity research through dedicated agencies and partnerships. For example, the U.S. ARPA-H agency awarded USD 144 million to the PROSPR program, while the Indian Institute of Science has launched the “Longevity India” initiative to address demographic transitions.
How will your daily life change if scientific advancements successfully extend the average human healthspan?